Short answer
RIGEL PHARMACEUTICALS INC (RIGL) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $79M (down 22.6% year over year) with net income of $17M.
Q2 2026 key financials · XBRL
- Revenue
- $79M
- −22.6% YoY · +33.8% QoQ
- Net income
- $17M
- −71.0% YoY · +99.8% QoQ
- Operating margin
- 30.0%
- EPS (diluted)
- $0.88
- −73.2% YoY · +100.0% QoQ
Source: XBRL data from the RIGEL PHARMACEUTICALS INC (RIGL) Q2 2026 10-Q on SEC EDGAR. USD.
RIGEL PHARMACEUTICALS INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Six-month revenue: TAVALISSE $84.7M, up 24% from $68.5M YoY
- Best performer: REZLIDHIA sales $17.0M, up 29% from $13.1M YoY
- Worst performer: GAVRETO sales $20.3M, down 2% from $20.8M YoY
- Capital deployment: $70.0M VEPPANU upfront payment and $40.0M revolving-credit borrowing at June 30, 2026
- Outlook: VEPPANU commercial availability expected mid-August 2026; R289 dose-expansion enrollment completion expected second half 2026
Risk Factors
- Newly added VEPPANU transition risk, triggered by June 11, 2026 license effectiveness following early HSR Act termination
- Most materially updated operational risk, with Arvinas and Pfizer retaining responsibilities before transfer and development funding capped at $40.0 million
- Compliance exposure from VEPPANU agreement, including anti-corruption, trade-controls and sanctions obligations with expedited termination provisions
- Near-term commercialization risk from manufacturing transfer delays, limited capacity and supply-chain disruptions affecting VEPPANU launch execution
- Financial risk from VEPPANU milestone payments and tiered royalties, potentially reducing product profitability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other RIGEL PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.